| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a564206d8584fa7090db18ff067e7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6007ba75a60c2216d98f751203c4b09c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2011-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83d56bca9d08c8e025972ff34d0cf6d6 |
| publicationDate |
2013-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8481038-B2 |
| titleOfInvention |
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| abstract |
The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9475871-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10294289-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8920800-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021528-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10537611-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10016484-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11697678-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702642-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10724014-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9169313-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9173957-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9192683-B2 |
| priorityDate |
2010-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |